» Articles » PMID: 38173275

Thrombotic Risk and Calculated Whole Blood Viscosity in a Cohort of Patients With New Diagnosis of Multiple Myeloma

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

The pathogenesis of venous thromboembolism in multiple myeloma is still poorly understood because multiple factors are involved. In particular, the increase in whole blood viscosity has a key role and, therefore, we performed an evaluation of some hemorheological determinants in multiple myeloma patients, putting them in relation to the thrombotic risk, with the aim to evaluate if an alteration of the hemorheological pattern was associated with a higher thrombotic risk. We performed an observational retrospective cohort study with data collected from January 2017 to September 2022. In a group of 190 patients with newly diagnosed multiple myeloma, we have examined the trend of calculated blood viscosity according to the Merrill formula, and we stratified the patients for the thrombotic risk in accordance with the IMWG/NCCN guidelines and with IMPEDE VTE score. Using the thrombotic risk stratification proposed by IMWG/NCCN any variation in calculated blood viscosity is evident, while, with the IMPEDE VTE score, we observed an increase in calculated blood viscosity in patients with "intermediate + high" risk. The calculated blood viscosity is higher in subjects presenting an "intermediate + high" thrombotic risk according to the IMPEDE VTE score. This association could therefore lay the groundwork for further research with the aim to confirm the role of hemorheological pattern in MM-related thrombotic risk.

Citing Articles

Calculated haemorheological profile and laboratory parameters in new diagnosed multiple myeloma patients: retrospective analysis according to survival.

Carlisi M, Lo Presti R, Spoto C, Mancuso S, Siragusa S, Caimi G Ther Adv Hematol. 2024; 15:20406207241298865.

PMID: 39583654 PMC: 11585042. DOI: 10.1177/20406207241298865.

References
1.
Chen Y, Magalhaes M . Hypoalbuminemia in patients with multiple myeloma. Arch Intern Med. 1990; 150(3):605-10. View

2.
Nayak B, Ojar-Taylor N, St John S, Swann S, Thom J, Thomas B . Significance of Serum Protein Electrophoresis in the Detection of Multiple Myeloma: A Diagnostic Interpretation of Patients with Varied Immunoglobulins. Int J Prev Med. 2021; 12:37. PMC: 8218806. DOI: 10.4103/ijpvm.IJPVM_222_18. View

3.
Gidaro A, Manetti R, Delitala A, Soloski M, Deliliers G, Castro D . Incidence of Venous Thromboembolism in Multiple Myeloma Patients across Different Regimens: Role of Procoagulant Microparticles and Cytokine Release. J Clin Med. 2022; 11(10). PMC: 9143530. DOI: 10.3390/jcm11102720. View

4.
Smith B, La Celle P . Blood viscosity and thrombosis: clinical considerations. Prog Hemost Thromb. 1982; 6:179-201. View

5.
Eby C . Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol. 2009; 145(2):151-63. DOI: 10.1111/j.1365-2141.2008.07577.x. View